Clinical Trials Logo

Hepatic Insufficiency clinical trials

View clinical trials related to Hepatic Insufficiency.

Filter by:

NCT ID: NCT05089981 Not yet recruiting - Clinical trials for Acute on Chronic Liver Failure(ACLF)

Intravenous NAC Use in ACLF Patients

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Primary Objective To evaluate the efficacy and safety of 72 hour NAC treatment regimen in the management of ACLF Secondary Objective To evaluate the six weeks mortality and length of hospital stay in ACLF patients treated with NAC Randomized, Double blind pilot study of IV N-Acetyl cysteine for the treatment of ACLF. Participants will be randomized into intervention and control arm using block randomization by computer generated random numbers. Efficacy will be assessed by clinical improvement in symptoms and signs of decompensated chronic liver disease (CLD). To assess safety degree of adverse reactions will be observed. Periodic assessments until 28 day will be done consisting of Physical exam, safety assessments, vital signs and lab tests. Dose of Drug: 72 hour regimen consisting of three doses of intravenous N-Acetyl cysteine will be used for a total dose of 300mg/kg. Number of Patients: 100 Accrual period: 15 months

NCT ID: NCT05036031 Not yet recruiting - Liver Cirrhosis Clinical Trials

Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study

TEA-ACLF
Start date: September 1, 2021
Phase:
Study type: Observational

The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

NCT ID: NCT04991259 Not yet recruiting - Acute Liver Failure Clinical Trials

To Evaluate the Safety and Efficacy of Preemptive Administration of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema

Start date: August 10, 2021
Phase: N/A
Study type: Interventional

In this prospective randomized controlled trial, investigator aim to evaluate the impact of early initiation of CRRT on outcomes in patients with acute liver failure with cerebral edema and hyperammonemia in improving cerebral edema and clinical outcomes. Investigator also aim to evaluate the effects of early initiation of CRRT on systemic hemodynamics (cardiac output and systemic vascular resistive index, extravascular lung water and lung permeability index), endothelial function and coagulation, microcirculation (as assessed by lactate clearance and central venous oxygen saturation), mitochondrial function. Patients with ALF who meet the inclusion and exclusion criteria. Group 1: CRRT initiation within the first 12 hours Group 2: CRRT would be initiated i) In patients with worsening hyperammonemia despite two sessions of plasma-exchange ii) Patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)

NCT ID: NCT04822922 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

Safety of UC-MSC Transfusion for ACLF Patients

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

Acute on chronic liver failure (ACLF) is a type of critically ill liver disease with high short-term mortality in liver disease. Liver transplantation is currently the only method to improve survival. Current clinical research evidence shows that mesenchymal stem cells can reduce the mortality of ACLF patients and are safe. This study aims to explore the safety of umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of ACLF. The study population is ACLF patients with 1-2 organ failures. To explore the safety of 3 doses of UC-MSCs, 16 patients need to be enrolled. The main observation indicators are the short-term and long-term safety of the treatment. All patients need to receive the standard medical treatment (SMT) at the same time. Stem cell treatment is given by intravenous infusion on the first, fourth, seventh, and tenth day. The occurrence of adverse events (AE) and serious adverse events(SAE) before and after the infusion will be observed. After the patient is discharged from the hospital, patients will be followed , the follow-up time is 5 years.

NCT ID: NCT04658407 Not yet recruiting - Clinical trials for Fulminating Hepatic Failure

Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Public Hospitals of Paris

DEVINHEF
Start date: April 1, 2021
Phase:
Study type: Observational

The main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with Severe, fulminating acute liver failure in the public hospitals of paris.

NCT ID: NCT04620148 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

TAK-242 in Patients With Acute Alcoholic Hepatitis

Start date: December 2021
Phase: Phase 2
Study type: Interventional

A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.

NCT ID: NCT04317222 Not yet recruiting - Clinical trials for Hepatic Encephalopathy

Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE

LTeCRRT
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Pretransplant hepatoencephalopathy (HE) markedly impacts recipient outcomes after liver transplantation. Intraoperative CRRT showed benefits but feasibility was much concerned. This study aims to observe the effect on consciousness recovery when initiating CRRT early in the post-transplant period in recipients with ACLF and overt HE.

NCT ID: NCT04195282 Not yet recruiting - Hepatitis B Clinical Trials

RL-1 Novel Human-derived Bio-artificial Liver Treatment in Patients of HBV Related ACLF

Start date: December 2019
Phase: N/A
Study type: Interventional

This study is to investigate the clinical efficacy and safety of RL-1 Novel Human-derived Bio-artificial Liver treatment in patients with Hepatitis b virus related acute-on-chronic liver failure.

NCT ID: NCT04186572 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

Usefulness of the Variation of the CLIF-C ACLF Score in Patients With Acute on Chronic Liver Failure

ARIHAC
Start date: December 2019
Phase:
Study type: Observational [Patient Registry]

Patients with Acute on Chronic Liver Failure (ACLF) have high short-term mortality. The use of a severity score could define the patient's prognosis and would help determine in whom the treatment is effective or futile.

NCT ID: NCT04051437 Not yet recruiting - Cirrhosis, Liver Clinical Trials

Plasma Exchange in Acute on Chronic Liver Failure

PLEXAR
Start date: August 15, 2019
Phase: Phase 3
Study type: Interventional

Acute on chronic liver failure (ACLF) is a distinct syndrome in patients with chronic liver disease with rapid clinical deterioration and has high short term mortality within one month.Despite aggressive clinical care, only half of the patients could survive an episode of ACLF. The investigators hypothesized that the early treatment with therapeutic plasma exchange with plasma and albumin in ACLF patients might improve overall survival in carefully selected patients by removing cytokines, chemokines and toxic substances.